title: High-dose sequential (HDS) chemotherapy for high-risk non-Hodgkin's lymphoma: long-term analysis and future developments.
authors.affiliation: Dipartimento di Medicina e Oncologia Sperimentale, Div. Universitaria di Ematologia, Torino, Italy. corrado.tarella@unito.it
authors.forename: C
authors.initials: C
authors.lastname: Tarella
authors.forename: A
authors.initials: A
authors.lastname: Cuttica
authors.forename: D
authors.initials: D
authors.lastname: Caracciolo
authors.forename: F
authors.initials: F
authors.lastname: Zallio
authors.forename: I
authors.initials: I
authors.lastname: Ricca
authors.forename: L
authors.initials: L
authors.lastname: Bergui
authors.forename: P
authors.initials: P
authors.lastname: Gavarotti
authors.forename: C
authors.initials: C
authors.lastname: Marinone
authors.forename: M
authors.initials: M
authors.lastname: Pagano
authors.forename: G
authors.initials: G
authors.lastname: Rossi
authors.forename: A
authors.initials: A
authors.lastname: de Crescenzo
authors.forename: A
authors.initials: A
authors.lastname: Salomone
authors.forename: M
authors.initials: M
authors.lastname: Ladetto
authors.forename: M
authors.initials: M
authors.lastname: Boccadoro
authors.forename: A
authors.initials: A
authors.lastname: Pileri
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D016465:Bone Marrow Purging; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D006085:Graft Survival; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction; D012307:Risk Factors; D000069283:Rituximab; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000009:adverse effects; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D003561:Cytarabine; D001761:Bleomycin; D000069283:Rituximab; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D002955:Leucovorin; D011241:Prednisone; D008727:Methotrexate